{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:46:30Z","timestamp":1792611990816,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jad.2021.12.134","type":"journal-article","created":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T17:19:23Z","timestamp":1641143963000},"page":"385-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":215,"special_numbering":"C","title":["Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"302","author":[{"given":"Nicolas A","family":"Nu\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boney","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehak","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Gardea","family":"Resendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J","family":"Prokop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Veldic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M","family":"Biernacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.12.134_bib0001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/da.20801","article-title":"Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression","volume":"28","author":"Abolfazli","year":"2011","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2021.12.134_bib0002","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1176\/appi.ajp.158.10.1617","article-title":"Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature","volume":"158","author":"Altshuler","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0003","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appelberg","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0004","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4088\/JCP.09m05355gre","article-title":"A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression","volume":"72","author":"Barbee","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4088\/JCP.v64n0407","article-title":"A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes","volume":"64","author":"Barbosa","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2013.05.079","article-title":"Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder","volume":"151","author":"Bauer","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jad.2021.12.134_bib114","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients with Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double Blind Study","volume":"70","author":"Bauer","year":"2009","journal-title":"J. Clin Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00004714-199608000-00006","article-title":"A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation","volume":"16","author":"Baumann","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0008","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.jad.2021.12.134_bib0009","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/070674370705200108","article-title":"Definition, assessment, and staging of treatment\u2014Resistant refractory major depression: a review of current concepts and methods","volume":"52","author":"Berlim","year":"2007","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.euroneuro.2007.03.009","article-title":"What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials","volume":"17","author":"Berlim","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2021.12.134_bib0083","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2021.12.134_bib0011","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00004850-199004000-00004","article-title":"Lithium as an adjunct in the treatment of major depression","volume":"5","author":"Browne","year":"1990","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/09540261.2020.1765748","article-title":"Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis","volume":"32","author":"Carter","year":"2020","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-8-73","article-title":"The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial","volume":"8","author":"Chaput","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0018","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0000000000000663","article-title":"Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study","volume":"37","author":"Cheon","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2021.12.134_bib0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2021.12.134_bib0022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"Corya","year":"2006","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2021.12.134_bib0023","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4088\/JCP.12m08093","article-title":"A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder","volume":"74","author":"Cusin","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0024","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4088\/JCP.v64n0911","article-title":"Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study","volume":"64","author":"DeBattista","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jad.2021.12.134_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","article-title":"Quetiapine augmentation of treatment-resistant depression: a comparison with lithium","volume":"23","author":"Dor\u00e9e","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2021.12.134_bib0027","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/jcp.0b013e31815abefb","article-title":"Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study","volume":"27","author":"Dunlop","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0028","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study","volume":"68","author":"Dunner","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2021.12.134_bib0029","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0030","first-page":"62","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2021.12.134_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2021.12.134_bib0032","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0033","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JCP.0b013e31822bb1d9","article-title":"A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression","volume":"31","author":"Fang","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0034","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0036","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.4088\/JCP.15m10470","article-title":"Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study","volume":"77","author":"Fava","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0037","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)","volume":"81","author":"Fava","year":"2012","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2021.12.134_bib0038","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4088\/JCP.v66n0112","article-title":"A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness","volume":"66","author":"Fava","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0039","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies","volume":"116","author":"Fekadu","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jad.2013.02.003","article-title":"Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study","volume":"149","author":"Franco-Chaves","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0042","first-page":"9","article-title":"American psychiatric association practice guidelines for the treatment of patients with major depressive disorder","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-0327(87)90046-2","article-title":"Failure of T3 to potentiate tricyclic antidepressant response","volume":"13","author":"Gitlin","year":"1987","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib115","article-title":"Study in patients with depression not responding to selective serotonin reuptake inhibitors","year":"2009","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.jad.2021.12.134_bib0044","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.4088\/JCP.13r08560","article-title":"Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials","volume":"74","author":"Goss","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder","volume":"19","author":"Grunze","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0046","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1742-7843.2011.00788.x","article-title":"Bupropion as an augmenting agent in patients of depression with partial response","volume":"110","author":"Gulrez","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jad.2021.12.134_bib0047","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2015.04.020","article-title":"Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study","volume":"66","author":"Han","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.12.134_bib0048","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archpsyc.1983.01790110077013","article-title":"Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression","volume":"40","author":"Heninger","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"issue":"d5928","key":"10.1016\/j.jad.2021.12.134_bib0049","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2021.12.134_bib0050","series-title":"Cochrane Handbook For Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jad.2021.12.134_bib0051","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ Br. Med. J."},{"key":"10.1016\/j.jad.2021.12.134_bib0052","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0165-1781(90)90029-5","article-title":"A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants","volume":"32","author":"Joffe","year":"1990","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2021.12.134_bib0053","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archpsyc.1993.01820170065008","article-title":"A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression","volume":"50","author":"Joffe","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0054","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/070674370605101209","article-title":"Lithium and triiodothyronine augmentation of antidepressants","volume":"51","author":"Joffe","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jad.2013.07.035","article-title":"Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)","volume":"151","author":"Kamijima","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0056","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1192\/bjp.166.1.80","article-title":"Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine","volume":"166","author":"Katona","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0057","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.12.134_bib0058","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"issue":"k4218","key":"10.1016\/j.jad.2021.12.134_bib0059","article-title":"Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)","volume":"363","author":"Kessler","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2021.12.134_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2021.12.134_bib0061","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/JCP.0000000000001475","article-title":"Association of optimal lamotrigine serum levels and therapeutic efficacy in mood disorders: a systematic review","volume":"41","author":"Kumar","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0062","doi-asserted-by":"crossref","first-page":"664","DOI":"10.4088\/JCP.v59n1204","article-title":"A Randomized, Double Blind, Placebo Controlled Trial of Buspirone in Combination with an SSRI in patients with Treatment Refractory Depression","volume":"59","author":"Land\u00e9n","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2021.12.134_bib0063","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2021.12.134_bib0064","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/acps.13154","article-title":"Thyroid hormone treatment in the management of treatment-resistant unipolar depression: a systematic review and meta-analysis","volume":"141","author":"Lorentzen","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.12.134_bib0065","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/npp.2013.334","article-title":"Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder","volume":"39","author":"Madhoo","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2021.12.134_bib0066","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2021.12.134_bib0067","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0447.2005.00602.x","article-title":"Treatment-resistant depression: resistant to definition?","volume":"112","author":"Malhi","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.12.134_bib0068","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0069","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/eb-2015-102088","article-title":"A primer on network meta-analysis with emphasis on mental health","volume":"18","author":"Mavridis","year":"2015","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.jad.2021.12.134_bib0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.20275","article-title":"Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study","volume":"24","author":"McIntyre","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2021.12.134_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0072","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JCP.0000000000000723","article-title":"The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis","volume":"37","author":"McIntyre","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2021.12.134_bib117","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0073","series-title":"Depression: the Treatment and Management of Depression in Adults (updated edition)","year":"2010"},{"key":"10.1016\/j.jad.2021.12.134_bib0074","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","article-title":"A comparison of lithium and T 3 augmentation following two failed medication treatments for depression: a STAR* D report","volume":"163","author":"Nierenberg","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00004714-200302000-00013","article-title":"Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants","volume":"23","author":"Nierenberg","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0076","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4088\/JCP.v63n0411","article-title":"Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study","volume":"63","author":"Normann","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0077","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bdi.12859","article-title":"Efficacy and tolerability of adjunctive modafinil\/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials","volume":"22","author":"Nunez","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0079","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1176\/appi.ajp.2015.14101251","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study","volume":"172","author":"Papakostas","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.jcp.0000246212.03530.fd","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression","volume":"26","author":"Patkar","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0081","series-title":"R: A language and Environment For Statistical computing. R Core Team","year":"2019"},{"key":"10.1016\/j.jad.2021.12.134_bib0082","first-page":"35","article-title":"Combination of citalopram and nortriptyline in treatment of moderate to severe major depression: a double-blind, Placebo-controlled Trial","volume":"1","author":"Raeisi","year":"2006","journal-title":"Iran J Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2021.12.134_bib116","first-page":"OT19037BR3","article-title":"Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies","volume":"81","author":"Rafeyan","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0084","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v69n0112","article-title":"Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial","volume":"69","author":"Ravindran","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0085","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0086","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jad.2016.07.006","article-title":"Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies","volume":"206","author":"Richards","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0087","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0088","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jad.2021.12.134_bib0089","first-page":"187","article-title":"Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study","volume":"10","author":"Santos","year":"2008","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/YIC.0b013e328014823d","article-title":"Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study","volume":"22","author":"Schindler","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0091","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2007-1014603","article-title":"Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study","volume":"22","author":"Sch\u00f6pf","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.jad.2021.12.134_bib0092","first-page":"40","article-title":"Meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"issue":"4","key":"10.1016\/j.jad.2021.12.134_bib0093","article-title":"Long-term efficacy and tolerability of adjunctive aripiprazole for major depressive disorder: systematic review and meta-analysis","volume":"23","author":"Seshadri","year":"2021","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.jad.2021.12.134_bib0094","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-3223(96)00307-1","article-title":"Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression-a double-blind controlled study","volume":"40","author":"Shahal","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11530280-000000000-00000","article-title":"Therapeutic options for treatment-resistant depression","volume":"24","author":"Shelton","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2021.12.134_bib0096","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0447.2007.01130.x","article-title":"Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder","volume":"117","author":"Shelton","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.12.134_bib0097","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2021.12.134_bib118","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance","volume":"66","author":"Shelton","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0098","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1176\/appi.focus.140202","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"14","author":"Spielmans","year":"2016","journal-title":"Focus"},{"key":"10.1016\/j.jad.2021.12.134_bib0099","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1192\/bjp.162.5.634","article-title":"Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses","volume":"162","author":"Stein","year":"1993","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2018.233","article-title":"Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis","volume":"214","author":"Strawbridge","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0101","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/acps.12712","article-title":"Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"135","author":"Szmulewicz","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.12.134_bib0102","series-title":"RStudio: Integrated Development Environment for R. RStudio Team","year":"2016"},{"key":"10.1016\/j.jad.2021.12.134_bib0103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"Thase","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2021.12.134_bib0106","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0105","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.12.134_bib0107","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4088\/JCP.13m08360","article-title":"A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram","volume":"74","author":"Trivedi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2021.12.134_bib119","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jad.2021.12.134_bib0108","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2021.12.134_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jad.2021.12.134_bib0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2045125313514767","article-title":"Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder","volume":"4","author":"Yoshimura","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.12.134_bib0111","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2012.07.008","article-title":"Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder","volume":"39","author":"Yoshimura","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2021.12.134_bib0112","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","author":"Zhou","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2021.12.134_bib0113","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00004714-198804000-00007","article-title":"Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study","volume":"8","author":"Zusky","year":"1988","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721014518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721014518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:58:40Z","timestamp":1759028320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721014518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":114,"alternative-id":["S0165032721014518"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.12.134","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.12.134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}